Tags : Biocon

Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

Mylan and Biocon Launch Semglee (insulin glargine injection) as Vials

Shots: The companies have launched Semglee (insulin glargine injection) in a vial and pre-filled pen at WAC of $147.98/ package of (5) 3ml pens and $98.65/ 10ml vial, representing the lowest WAC for any long-acting insulin glargine The US FDA has approved Semglee for the same indications as to its reference product Sanofi’s Lantus, thus […]Read More

Biocon Collaborates with Voluntis on Digital Therapeutics for Insulins

Shots: The two companies collaborated to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The collaboration allows Biocon to offer Insulia to T2D patients across several markets globally Biocon aspires to reimagine the patient ecosystem by developing a technology-dependent operating model enabling personalization of care, thus going beyond the product […]Read More

Weekly Snapshot Jul 13- 17, 2020

 1.  Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis Published: Jul 17, 2020 | Tags: Eli Lilly, Reports, Results, Mirikizumab, P-III, OASIS-2, Study, Treat, Moderate, Severe, Plaque Psoriasis 2.  Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced / Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid […]Read More

Weekly Snapshot (Jul 13- 17, 2020)

 1.  Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis Published: Jul 17, 2020 | Tags: Eli Lilly, Reports, Results, Mirikizumab, P-III, OASIS-2, Study, Treat, Moderate, Severe, Plaque Psoriasis 2.  Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced / Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid […]Read More

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

PharmaShots Weekly Snapshot (Jun 08- 12, 2020)

 1. Medtronic Receives CE Mark for MiniMed 780G Insulin Pump to Treat Type 1 Diabetes                                                Published: Jun 11, 2020 | Tags: Medtronic, Receives, CE, Mark, MiniMed 780G, Insulin Pump, Treat, Type 1 Diabetes 2.  Takeda to Divest OTC and Select Non-core Assets to Celltrion for ~ $278M        Published: Jun 11, 2020 | Tags: Takeda, Divest, [&Read More

Mylan and Biocon Receive the US FDA’s Approval for Semglee

Shots: The US FDA’s approval is based on comprehensive analytical, preclinical, and clinical programs (including the INSTRIDE (1&2) studies assessing MYL-1501D (qd) vs Lantus in 558 T1DM & 560 T2DM patients for 52wks. & 24wks. respectively. The 1EPS is changed from baseline in HbA1c after 24 wks. The INSTRIDE demonstrated no difference in safety, efficacy, […]Read More

Insights+ Key Biosimilars Events of May 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More